Connect with us

Media & Technology

The Buzz on Hexo Corp (TSX: HEXO) (OTCMKTS: HYYDF)

Published

on

Hexo Corp (OTCMKTS: HYYDF) is one of the country’s lowest-cost producers that is rapidly increasing its production capacity in the lead up to the adult-use cannabis market.

The global legal cannabis market is booming! according to a recent report published by Forbes, Brightfield Group projects that the global cannabis market was worth $7.7 billion in the end of 2017, and is projected to reach $31.4 billion by 2021 with the US currently dominating the market. According to a new report from Deloitte the legal recreational cannabis industry could be worth $7 billion annually in Canada by next year.

Hexo Corp (TSX: HEXO) (OTCMKTS: HYYDF) currently operates with over 310,000 sq. ft. of production capacity with construction on another 1,000,000 sq. ft. expansion set to be complete by year end. HEXO will serve the adult-use market under the HEXO brand, while continuing to serve its medical cannabis clients through the well-known Hydropothecary brand.

HEXO also holds an interest in a 2,004,000 sq. ft. facility in Belleville, Ontario. The building, previously used as a Sears distribution center, will be owned in a joint venture with Olegna Holdings Inc. Initially, HEXO plans to lease up to 500,000 sq. ft. of the space from the joint venture. The proposed use of the building is conditional on the city approving the rezoning application.

HEXO is making progress outside Quebec, the Company recently entered into a supply agreement with the Ontario Cannabis Store. Under the deal, the Company will supply the province with its award-winning Elixir product line, along with its newly launched Fleur de Lune, an intimate cannabis oil. The Elixir product offering includes several formulations such as THC, CBD, or 1:1 in either a peppermint oil or a medium-chain triglyceride (MCT) carrier oil. Elixir and Fleur de Lune are smoke-free, easy-to-use and will be sold in childproof packaging.

On Friday HEXO reported fiscal 2018 fourth quarter results; Revenue for the fourth quarter ended July 31, 2018 increased 64% to $1,410,656 compared to $862,000 in the same period in Fiscal 2017. Higher revenue was driven mainly by increased Elixir and H2 (mid-range line) sales volume, as Elixir was introduced in late Q4’17 and H2 sales volume increased by 70%. Compared to the prior quarter, the sequential revenue increase was 14%, reflecting a higher total of volume sold, primarily driven by a 31% increase in oil sales. For the twelve months ended July 31, 2018, revenue increased 20% to $4,934k compared to $4,097k in the same period in Fiscal 2017. Sales volume increased 33% to 538,886 gram equivalents, compared to 404,158 in the same prior year period.

To Find out the inside Scoop on Hexo Corp Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

Last month Hexo announced the first harvest of plants from its new 250,000 sq. ft. greenhouse. HEXO’s 250,000 sq. ft. greenhouse expansion, together with the manufacturing expansion, brings the Company’s total production space to over 310,000 sq. ft. Construction on the Company’s one million square foot facility is set to be complete by year-end.

The Company also recently signed a contract to manage a warehouse and distribution center for Quebec adult-use webstore orders for the Société québécoise du cannabis (“SQDC”). HEXO and Metro will work together to run the modern 58,000 sq. ft. facility located in Montreal. The facility consists of a warehouse and distribution center, will house product from all the licensed producers who have contracts with the SQDC and will contribute to the creation of 35 new jobs in Quebec.

Over the past quarter HEXO moved towards final preparations for the adult-use cannabis market. With two additional supply deals, this time in Ontario and in British Columbia, the establishment of a joint venture with Molson Coors Canada to develop cannabis-infused non-alcoholic beverages, a first step towards going global.

On October 22 HEXO said Taking its preferred supplier status with the Société québécoise du cannabis (SQDC) and its deals with Ontario and British Columbia seriously, licensed cannabis producer HEXO is proud to not only have delivered on all orders but to have also replenished stock across the country.

HEXO CEO and co-founder Sébastien St-Louis. said “in its 310,000 sq. ft. production facility, HEXO has produced enough of its high quality dried flower, oils, milled flower and pre-rolled cones to meet the initial demand and to send resupply shipments ahead of schedule, ensuring stores and distribution centres have undisrupted access to products. The company reports that it has pulled all stops to meet the demand, shipping several times over the weekend. We’ve been focused on executing all of our plans for several weeks, and I am proud that our team’s dedication and capability has meant that customers’ access to HEXO product has been dependable. Sales have been good, and we’ve been able to keep up. We said we were ready; now we have proved it.”

We have a Monster Pick Coming. Subscribe Right Now!

Currently trading at a market valuation exceeding $1.5 billion HEXO recently reported revenue for the fourth quarter ended July 31, 2018 increased 64% to $1,410,656 compared to $862,000 in the same period in Fiscal 2017. Hexo is one exciting Company; Hexo currently has over 310,000 sq. ft. of production capacity and construction on another 1,000,000 sq. ft. expansion set to be complete by year end. Hexo  holds an interest in a 2,004,000 sq. ft. facility in Belleville, Ontario. HEXO also has a joint venture with Molson Coors Canada to pursue opportunities to develop non-alcoholic, cannabis-infused beverages. We will be updating on HEXO when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with HEXO.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in HEXO either long or short and we have not been compensated for this article

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Media & Technology

Global Tech Industries Group Inc (GTII) rally could be just getting started

Published

on

Small-cap stocks have seen a significant increase in the first weeks of January, a trend that is often seen at the start of a new year. This presents an opportunity for investors to capitalize on the surge before it dissipates. The Russell 2000 index, which follows small-cap stocks, has shown a 7.4% increase as of Monday’s close, outperforming the large-cap Russell 1000, which has risen by 5%, and the S&P 500, which has increased by 4.5%.

The “January Effect” rally, where small caps surpass large caps, is a common phenomenon. One such stock that may be benefitting from this January effect is GTII. Global Tech Industries Group Inc (GTII) last traded at $1.86 and closed with double-digit gains of 11.08%.  GTII has a 52-week range of $0.4302 – $8.9700, suggesting a tremendous upside potential from the current levels.

To Find out the inside Scoop on GTII, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

What caused the surge in GTII share prices?

For the uninitiated,  Global Tech Industries Group, Inc. (OTCQB: GTII) is a Nevada-based public company focused on acquiring cutting-edge technologies. Last week, GTII announced Board appointed Donald Gilbert to lead a newly created task force that will investigate illegal trading in GTII’s shares. The task force will be responsible for examining and assessing the possibility of illegal and deceptive trading practices by various market players, including market makers, brokers, and hedge funds. In addition, the task force will also advise the Board on potential legal actions against market participants suspected of engaging in unlawful trading activity concerning GTII’s shares. Based on its initial assessment, the task force will also advise the Board on presenting evidence of potential illegal trading activity concerning GTII’s shares to relevant government and regulatory agencies. In essence, Mr. Gilbert will lead the efforts necessary for safeguarding the interests of GTII’s shareholders.

For more on GTII, Subscribe Right Now!

Creatd, Inc.(OTCQB: CRTD) announced today that it had extended the no-shop period in its Letter of Intent with Global Tech Industries Group, Inc. (GTII) for its planned acquisition. Although there’s no guarantee a deal will be reached, both firms continue to evaluate the deal through due diligence, and Creatd is exploring a collar structure to potentially value its shares at $3.00 to $5.00 per share.

It would be interesting to see if GTII news gets picked up by retail investors causing a further surge in stock prices. We will update GTII when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s going on with GTII.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in GTII either long or short and we have not been compensated for this article

Continue Reading

BioPharma

Cosmos Holdings Inc (NASDAQ: COSM) Huge Short Position Panicks as COSM Rockets Up the Charts

Published

on

Cosmos Holdings Inc (NASDAQ: COSM) is rocketing up the charts northbound since reversing off $0.0675 lows earlier this month where we first gave the heads up on COSM at around a dime in our article here. Since than COSM has rocketed northbound recently surpassing $0.60 per share with speculators pointing at $1 as the next stop. In our previous article on COSM on November 13 when COSM was $0.10 we stated: “COSM was trading well over $3 at the beginning of this year but has been heavily shorted since than with current estimates of well over 5 million shares sold short and almost the entire public float sold short. 

While COSM has been heavily shorted into oblivion, the Company is actually doing quite well recently reporting revenues for the 3 months ended September 30 were $12 million. The Company is successfully developing their business recently closing a deal with Iberica, a European Airline, for in flight distribution of their products. The CEO has bought millions of shares at current levels and COSM is beginning to go viral on social media trending on the sub reddit Short Squeeze, Number #1 on Stocktwits and multiple videos being made on YouTube about a massive short squeeze taking place in small caps. 

COSM Friday December 2, 4PM Close Update: COSM had a wild trading day on Friday dropping to $0.42 in the morning before rocketing up to $0.61 highs. This was followed by another drop to the $0.47 range before COSM rocketed up in late afternoon trading, closing at $0.53 on 205 million shares traded. COSM was up 33% on the day on around $110 million in dollar volume. COSM is setup for an enormous week ahead, looking to overtake the $0.845 from Monday and embark on a blue-sky breakout with $1 as the first stop. We gave the heads up on COSM when the stock was below $0.10 per share at the beginning of November. We will be updating on COSM as soon as anything new happens so make sure you are subscribed to Microcapdaily by entering your email in the box below.  

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

No alternative text description for this imageCosmos Holdings Inc (NASDAQ: COSM) is a global healthcare group that was incorporated in 2009 and is headquartered in Chicago, Illinois. Cosmos Health is engaged in the nutraceuticals sector through its own proprietary lines of products “Sky Premium Life” and “Mediterranation.” Additionally, the Company is operating in the pharmaceutical sector through the provision of a broad line of branded generics and OTC medications and is involved in the healthcare distribution sector through its subsidiaries in Greece and UK serving retail pharmacies and wholesale distributors. Cosmos Health is strategically focused on the R&D of novel patented nutraceuticals (IP) and specialized root extracts as well as on the R&D of proprietary complex generics and innovative OTC products. Cosmos has developed a global distribution platform and is currently expanding throughout Europe, Asia and North America. Cosmos Health has offices and distribution centers in Thessaloniki and Athens, Greece and Harlow, UK. 

The Number #2 post on the subreddit ShortSqueeze currently is titled: COSM about to test resistance. A pump through $0.66 and lift off to over $1.00 is possible now. 

In another post on COSM in the subreddit ShortSqueeze rubio2430 states: “$COSM you cant make this stuff up. this baby is ready for space. the shorts are burying themselves on the daily. constant pr’s, growing fundamentals, no plans on dilutions, dual listing on upstream soon—the list goes on! 

nimble_broccoli replied: Why this is a good play: 

1.) Extremely tiny Marketcap 2.) CEO buying 15’000’000 shares 3.) Good fundamentals, unlike other plays, they actually sell products valued around 10x the valuation. Q1/22 was profitable. 4.) Getting momentum on social media (Reddit Twitter, YT) 

Next catalysts: -Info that they will not be delisted from NASDAQ -Degen and Retail FOMO kicking in -Shorts starting to cover their asses 

In addition, consider this: The stock was somewhere between USD 2 and USD 12 the past ~8 years. Most Hodlers bought back then, do you think they will sell now? Do your own thinking but if one of my stocks dropped 80+ % i d not sell, i d just hope for a miracle or ride it out. Thus, not many regular buy&hold holders of the stock are expected to sell. 

Cosmos operates in the business of full-line pharmaceutical wholesale distribution and serves approximately 1,500 independent retail pharmacies and 40 pharmaceutical wholesalers in Greece region by providing brand-name and generic pharmaceuticals, over-the-counter medicines, vitamins and nutraceuticals. Cosmos invests in technology to enhance safety, distribution and warehousing efficiency and reliability. Specifically, the Company operates a fully automated warehouse system with three robotic systems, two ROWA™ types and one A-frame type, that ensure 0% error selection rate, accelerate order fulfillment, and yield higher cost-efficiency in our distribution center. Cosmos has 3 operating subsidiaries including:

SkyPharm
Sky Pharm SA is headquartered in Thessaloniki, Greece. Sky Pharm trades the excess amounts of about 500 medicines that can be exported within the EU countries. We buy from Greek wholesale pharmaceutical companies and multinational pharmaceutical manufacturers, and export to European markets where demand and prices are substantially higher.
.
DHN
Decahedron Ltd. is a pharmaceutical wholesaler incorporated in the UK in August 2011. It is audited by the MHRA under European GDP (Good Distribution Practices). They are also a full member of the EAEPC and have been audited by TÜV on their behalf.
.
Cosmofarm
Founded in 1994, Cosmofarm is a fully licensed pharmaceutical wholesale company operating in the greater Athens area. The company is approved and authorized by the National Organization for Medicines under Good Distribution Practices to distribute a comprehensive range of pharmaceutical products. Cosmofarm’s core activity is sourcing, procuring, and distributing branded.
.
To Find out the inside Scoop on COSM Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

COSM

Image

COSM business is strong and Q3 highlights include closing a $7.5M capital raise via public offering and signing an exclusive agreement to market and distribute Nickelodeon’s SpongeBob and PAW Patrol kids’ vitamins in Greece and Cyprus, aiming to reach out 11,000 pharmacies and 120 wholesalers in Greece and 780 pharmacies in Cyprus. They also executed a letter of intent for a strategic co-venture agreement with Smart for Life (SMLF) to cross market products and services in their reciprocal markets. COSM also entered into an LOI to acquire ZipDoctor Inc., and entered into an agreement with Virax Biolabs (VRAX), to become the distributor of Monkeypox Virus Real-Time PCR Detection Kits, having the exclusive distribution rights for Greece and Cyprus, with the opportunity to distribute the test kits across Europe on a non-exclusive basis. SkyPharm officially launched its first Sky Premium Life products on Amazon in the United States. Cosmos targets having all 85 SKUs listed on Amazon by year end. COSM entered into an LOI to acquire Pharmaceutical Laboratories CANA S.A., and another LOI to acquire LIFE NLB, Ltd.’s product portfolio, including Bone-Vio® and Bone-X, related to bone health targeting the human gastrointestinal microbiome. 

Last week COSM announced its Sky Premium Life luxury food supplement brand will be sold on Ronda, the official inflight magazine of the airline company Iberia of BRITISH AIRWAYS group. Ronda is available free of charge to the over 10 million passengers who fly Iberian Airlines annually. Iberia Airlines, majority owned by British Airways, has a fleet of 147 aircrafts and engages in over 600 daily flights. 

https://twitter.com/nxtplse/status/1597365583934545920

For More on COSM Subscribe Right Now!

Currently trading at a $36 million market valuation COSM os is 92,008,281 the Company recently reported Q3 Revenues of $12 million down a bit from the same time last year due to a high variation in FX differences between EUR and GBP to USD. COSM was trading over $4 this time last year however OS has increased substantially since then.  COSM is an exciting opportunity in small caps; the stock was shorted into oblivion and currently there are minimum 5.8 million shares short and was way oversold to pennies and it looked as if it would definitely get delisted by the Nasdaq however, led by able CEO Grigorios Siokas, Cosmos is fighting back. Mr. Siokas continues to buy more COSM at current price levels, putting his money where his mouth is as COSM rockets towards $1 which is now just a day and half away if the stock continues up at the same trend.  We will be updating on COSM when more details emerge so make sure you are subscribed to Microcapdaily.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in COSM either long or short and we have not been compensated for this article.

Continue Reading

BioPharma

Cosmos Holdings Inc (NASDAQ: COSM) Heating Up as Co Looks to Take on Massive 5 million Share Short Position

Published

on

Cosmos Holdings Inc (NASDAQ: COSM) is making a rapid move up the charts since recent reversing off $0.0675 lows. The stock was trading well over $3 at the beginning of this year but has been heavily shorted since than with current estimates of well over 5 million shares sold short and almost the entire public float sold short. COSM is quickly emerging as the latest short squeeze at the top of speculators watch lists and is currently trending on stocktwits and the sub reddit ShortSqueeze on Reddit. 

The Company is fighting back against the shorts and planning a lawsuit and CEO Grigorios Siokas recently put his money where his mouth is when he bought 12,500,000 shares of the stock at $0.12 average for about $1.5 million. While in danger of being delisted from the Nasdaq if they don’t get the stock price back over $1 by the end of November the Company is doing well recently reporting its first ever net income on $13,208,504 in revenues for the 3 months ended June 30, 2022. Cosmos is also acquiring ZipDoctor Inc. from American International Holdings Corp (AMIH) 

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Cosmos Holdings Inc (NASDAQ: COSM) is an international healthcare group that was incorporated in 2009 and is headquartered in Chicago, Illinois. On August 2, 2022, the Company filed a Fictitious Firm Name Certificate in Nevada to do business under the name Cosmos Health, Inc. and will seek shareholder approval at its annual shareholders meeting scheduled for December 2, 2022 to amend its Articles of Incorporation for the name change. Cosmos Health is engaged in the nutraceuticals sector through its own proprietary lines of products “Sky Premium Life” and “Mediterranation.” Additionally, the Company is operating in the pharmaceutical sector through the provision of a broad line of branded generics and over-the-counter (“OTC”) medications and is involved in the healthcare distribution sector through its subsidiaries in Greece and UK serving retail pharmacies and wholesale distributors.  

Cosmos operates in the business of full-line pharmaceutical wholesale distribution and serves approximately 1,500 independent retail pharmacies and 40 pharmaceutical wholesalers in Greece region by providing brand-name and generic pharmaceuticals, over-the-counter medicines, vitamins and nutraceuticals. Cosmos invests in technology to enhance safety, distribution and warehousing efficiency and reliability. Specifically, the Company operates a fully automated warehouse system with three robotic systems, two ROWA™ types and one A-frame type, that ensure 0% error selection rate, accelerate order fulfillment, and yield higher cost-efficiency in our distribution center. Cosmos has 3 operating subsidiaries including:

SkyPharm
Sky Pharm SA is headquartered in Thessaloniki, Greece. Sky Pharm trades the excess amounts of about 500 medicines that can be exported within the EU countries. We buy from Greek wholesale pharmaceutical companies and multinational pharmaceutical manufacturers, and export to European markets where demand and prices are substantially higher. The …
DHN
Decahedron Ltd. is a pharmaceutical wholesaler incorporated in the UK in August 2011. It is audited by the MHRA under European GDP (Good Distribution Practices). They are also a full member of the EAEPC and have been audited by TÜV on their behalf. They import and export branded, generic and …
Cosmofarm
Founded in 1994, Cosmofarm is a fully licensed pharmaceutical wholesale company operating in the greater Athens area. The company is approved and authorized by the National Organization for Medicines under Good Distribution Practices to distribute a comprehensive range of pharmaceutical products. Cosmofarm’s core activity is sourcing, procuring, and distributing branded

https://twitter.com/ChairmanOtc/status/1590877348752420866

To Find out the inside Scoop on COSM Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

COSM

ImageOn August 22 Cosmos provided a business update and reported financial results for the second quarter and six months ended June 30, 2022. Revenues were $13,208,504 for the 3 months ended June 30, 2022 compared to $14.8 million for the same period last year. 

Greg Siokas, Chief Executive Officer of Cosmos Health, stated, “We increased our profitability for the first half of 2022 due to the increase of gross profit margin to 14.2% from 11.5% for the respective period of 2021. This increase is attributed mainly to the organic growth of our proprietary nutraceutical brand, Sky Premium Life® (“SPL”). We achieved positive income from operations of $0.2 million for the first half of 2022 compared to a loss of $3.1 million in the same period last year and positive EBITDA of $0.8 million for the first half of 2022 compared to a loss of $2.8 million for the same period last year. Gross profit increased by 23.0% to $3.7 million for the six months ended June 30, 2022. We continue to carefully manage expenses and reduced operating expenses by nearly 43.7% and 41.9% for the three and six months ended June 30, 2022, respectively. During the quarter, we launched a new premium line of nutritional supplements, Mediterranation. The Mediterranation line uses organic herbs and plant extracts such as crataegus, hibiscus, dittany of Crete, oregano, mastic and kritamos, found in specific regions in Greece and the Mediterranean. These unique formulations contain a proprietary blend of vitamins and minerals and are made with the highest quality raw materials. There is high demand among consumers for supplements that utilize high quality Mediterranean ingredients, such as polyphenols, which possess antioxidant and anti-inflammatory properties. We expect the launch of the Mediterranation line will further enhance our growth strategy and we look forward to expanding the product line into new global markets through our growing distribution channels. We also launched our SPL products on Amazon Singapore and are in the process of launching on Amazon United States and Amazon Canada in the third quarter of 2022. These new markets provide an untapped growth opportunities and new audiences for our proprietary SPL brand. Our goal is to grow our portfolio of branded nutraceuticals and reach up to 150 SKUs by the end of 2022.” 

Earlier this year Cosmos announced an LOI to acquire ZipDoctor Inc. from American International Holdings Corp (AMIH). AMIH will continue to manage all aspects of the day-to-day operations of ZipDoctor including product development, marketing, and operational support. ZipDoctor Inc., is a direct-to-consumer subscription-based telemedicine platform, that expects to provide its customers affordable, unlimited, 24/7 access to board certified physicians and licensed mental and behavioral health counselors and therapists. ZipDoctor’s online telemedicine platform will be available to customers across the United States and offers English and Spanish coverage with virtual visits taking place either via the phone or through a secured video chat platform. 

On October 17, 2022, Cosmos entered into a Securities Purchase Agreement with certain institutional investors (the “Purchasers”), pursuant to which the Company agreed to issue and sell, in a public offering, an aggregate of $7,500,000 of securities, consisting of (i) 62,500,000 shares of Common Stock, (ii) pre-funded Warrant in lieu of shares of Common Stock, and (iii) warrants to purchase 125,000,000 shares of Common Stock (the “Common Warrants” and collectively with the Pre-Funded Warrants, the “Warrants”).  Under the terms of the Purchase Agreement, the Company agreed to sell one share of its Common Stock or a Pre-Funded Warrant and two Common Warrants for each share of Common Stock or Pre-Funded Warrant sold at a unit price of $0.12.  For each of 15,662,603 Pre-Funded Warrant sold in the Offering, the number of shares of Common Stock offered were decreased on a one-for-one basis. 

https://twitter.com/AirGoodman24/status/1591938222548189186

 For More on COSM Subscribe Right Now!

Currently trading at a $10 million market valuation COSM is the latest potential short squeeze at the top of speculators watch lists. With $35 million in current liabilities and an inability to collect on accounts receivables that currently stand at over $25 million COSM stock has lagged even as the Company reports its first ever net income on $13,208,504 in revenues for the 3 months ended June 30, 2022. The short position on COSM has grown to well over 5 million shares short and currently the entire public float is sold short. Now that the cat is out of the bag and the stock is surging northbound COSM short squeeze should be at the top of small cap speculators watch lists. We will be updating on COSM when more details emerge so make sure you are subscribed to Microcapdaily.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in COSM either long or short and we have not been compensated for this article.

Continue Reading

Trending

© All rights reserved.

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.